Trial · NCT04222972
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) | Arm A: Treatment Period- SOC | 9.0 | 95% Confidence Interval 7.1 to 11.5 | months | |
| Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) | Arm B: Treatment Period- Pralsetinib | 18.7 | 95% Confidence Interval 11.1 to 25.2 | months | |
| Arm A vs Arm B: Objective Response Rate (ORR) | Arm A: Treatment Period- SOC | 41.6 | 95% Confidence Interval 32.40 to 51.24 | percentage of participants | |
| Arm A vs Arm B: Objective Response Rate (ORR) | Arm B: Treatment Period- Pralsetinib | 65.5 | 95% Confidence Interval 55.79 to 74.26 | percentage of participants | |
| Arm A vs Arm B: Overall Survival (OS) | Arm A: Treatment Period- SOC | 39.8 | 95% Confidence Interval 39.8 to NA | months | |
| Arm A vs Arm B: Overall Survival (OS) | Arm B: Treatment Period- Pralsetinib | NA | 95% Confidence Interval 29.6 to NA | months | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Arm A: Treatment Period- SOC | AEs | 104 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Arm B: Treatment Period- Pralsetinib | AEs | 108 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Arm C: Crossover Period- Pralsetinib | AEs | 38 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Arm A: Treatment Period- SOC | SAEs | 38 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Arm B: Treatment Period- Pralsetinib | SAEs | 67 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Arm C: Crossover Period- Pralsetinib | SAEs | 22 | Participants | |
| Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | Arm A: Treatment Period- SOC | Baseline ECOG Score 0: Post-baseline Score 0 | 14 | Participants | |
| Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | Arm B: Treatment Period- Pralsetinib | Baseline ECOG Score 0: Post-baseline Score 0 | 18 | Participants | |
| Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | Arm C: Crossover Period- Pralsetinib | Baseline ECOG Score 0: Post-baseline Score 0 | 3 | Participants | |
| Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | Arm A: Treatment Period- SOC | Baseline ECOG Score 0: Post-baseline Score 1 | 28 | Participants | |
| Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | Arm B: Treatment Period- Pralsetinib | Baseline ECOG Score 0: Post-baseline Score 1 | 22 | Participants | |
| Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | Arm C: Crossover Period- Pralsetinib | Baseline ECOG Score 0: Post-baseline Score 1 | 7 | Participants | |
| Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | Arm A: Treatment Period- SOC | Baseline ECOG Score 0: Post-baseline Score 2 | 0 | Participants | |
| Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score | Arm B: Treatment Period- Pralsetinib | Baseline ECOG Score 0: Post-baseline Score 2 | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04222972/results